secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-09-12T23:59:59+00:00
Accession:  0001641172-25-027247
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma showcases CDI-988 at calicivirus conference, notes FDA clearance for Phase 1b challenge study
--------------------------------------------------------------------------------

- President/co-CEO Sam Lee presented CDI-988 Phase 1 data at 9th International Calicivirus Conference (Sept 7–11) in Banff.
- CDI-988 is a first oral antiviral candidate for norovirus, with broad-spectrum activity against GII.4 and GII.17.
- Phase 1 showed favorable safety and tolerability, with no serious adverse events.
- FDA cleared a Phase 1b human challenge study for norovirus prophylaxis/treatment; expected start before end of 2025.
- CDI-988 targets a conserved region in 3CL viral proteases, designed with Cocrystal's proprietary structure-based platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225027247/0001641172-25-027247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225027247/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-027247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer